Abstract
Levels of C3, properdin, factor B, and C3 to C9 activity were markedly reduced in cord sera taken from 94 normal newborn infants. Nevertheless, cord serum supported complete activation of its own alternative pathway by zymosan or CoF. Lysis of a target cell, however, was defective; nearly 75% of cord sera had reduced rabbit erythrocyte CH50 titers. These were partially increased by the addition of factor B and properdin, and totally restored by adding factor B, properdin, and C3 to C9. Therefore, although the alternative pathway of the neonate is intact, it appears to be limited in its ability to generate an adequate number of stable and active enzymatic sites on a target cell membrane.
References
Oct 1, 1976·The Journal of Experimental Medicine·R G MedicusH J Müller-Eberhard
Oct 1, 1975·Pediatric Research·P A Feinstein, S R Kaplan
Sep 1, 1965·Immunochemistry·G ManciniJ F Heremans
Nov 1, 1981·Transfusion·R G StraussJ R Urmson
Citations
Jul 1, 1981·The Journal of Pediatrics·R ShapiroA F Malan
Dec 13, 2012·Pediatric Research·Hildegunn N GransloTrond Flægstad
Oct 1, 1980·Archives of Disease in Childhood·B Pelet
Dec 1, 1980·Gut·B J PotterD P Jewell
Jan 1, 1987·Acta paediatrica Scandinavica·A FiettaG Rondini
Apr 1, 1980·Clinical Immunology and Immunopathology·R A RichmanR E Spitzer
Mar 1, 1984·Clinical Pediatrics·A Petru, P H Azimi
Jan 20, 2004·Journal of Clinical Laboratory Analysis·Robert F RitchieOlga Navolotskaia
Sep 24, 2005·Stroke; a Journal of Cerebral Circulation·Vadim S TenDavid J Pinsky
Apr 1, 1980·Archives of Disease in Childhood·V Larcher, A P Mowat
Mar 1, 1997·Pediatric Research·E P ZilowG Zilow
Apr 27, 2000·The Pediatric Infectious Disease Journal·F E BablE R Cooper
Dec 16, 1998·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·J SonntagM Obladen
Jun 1, 1983·Current Problems in Pediatrics·K L CatesM Ballow
Dec 13, 2006·Current Problems in Pediatric and Adolescent Health Care·Robert M Lawrence, Camille A Pane